Skip to content
Precision for Medicine
Early Access to Whitepaper

Beyond Geography: A Former Regulator’s Perspective on Multiregional Oncology Trials

cf-ctdna cf-ctdna

Clinical Trial Design that Maximizes Biomarker-Driven Insights

Intuitive, biomarker-driven clinical trials, designed with Precision
Patient populations can be refined, rather than randomized, based on umbrella or basket designs, depending on the nature of the study drug and relevant indications as well as the different types of clinical research being performed. Our team of Precision experts focuses on protocol nuances to match each patient with the optimal study population and gain valuable insights from biomarkers. This results in a “rapid-to-market” strategy precisely tailored to your product.
  • Basket trials_Doctors discussing results
    Explore

    Basket & Umbrella Trials

    We carefully select sites for both their scientific expertise and patient recruitment success, then maintain constant communication for nimble decision-making that accelerates proof-of-concept for various types of clinical studies.

     
  • CTD_Hero
    Explore

    Biomarker Clinical Trials

    We use diagnostic, prognostic and predictive biomarkers to enable informed decision making, resulting in a faster approval time and a statistically higher rate of commercialization.

     
  • iStock-1177064020 (1)

    Master Protocol Trials

    We stay at the forefront of clinical trial design, pairing statistical rigor and biomarker expertise to design and implement master protocol trials.

     
PDF-pg34-(1)

Informed by biomarkers.
Designed for insights.

Biomarker-driven science seamlessly integrated with clinical development.

A precision-driven approach ensures that robust molecular-level data positions the right patient with the right drug. With our expertise in translational medicine and clinical trial execution, every trial design is informed by advanced biomarkers and is purpose-built for improved insights and streamlined trial execution.

Integrated solutions can optimize your study’s strategy and trial design. Harnessing the efficiency of biomarker-driven studies not only accelerates the trial process but also ensures that Precision delivers clinical developments faster and with greater insight compared to conventional trial designs.

Physicians reviewing patient data_case study
Case Study

A basket trial and an accelerated pathway to proof-of-concept

As part of a long-term collaboration, Precision for Medicine used an adaptive approach to explore multiple tumor types concurrently, accelerating the pathway to proof-of-concept. 

Targeted patient:

The study targets subjects with a specific rare mutation. The protocol identifies a list of possible mutations. All patients are required to have genomic assays completed with the mutation identified before enrollment will be considered.

Study design:

The initial protocol had 8 different tumor-specific mutation cohorts in a Simon’s 2-stage design. For the first stage, 7 patients are enrolled; if 1 response is observed the cohort expands to stage 2. If no responses are identified, the cohort may be closed, with new tumor types identified. Tumor types are ruled “in” for further exploration (up to the point of accelerated approval or phase 3 investment) or “out” within this trial.

Download this case study to learn more.

Download case study

Insights from Precision’s experts

Stay ahead with the latest insights from Precision’s team of experts. Discover valuable perspectives, updates, and strategies to design optimal global clinical programs.

Read: Case Study: Delivering Pivotal Data in Phase 3 R/R Multiple Myeloma Case Study: Delivering Pivotal Data in Phase 3 R/R Multiple Myeloma

Clinical Trials - Oncology

Case Study: Delivering Pivotal Data in Phase 3 R/R Multiple Myeloma

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1767769678459, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover
Read: MHRA's International Recognition Procedure: Fast-Track Access to the UK Market MHRA's International Recognition Procedure: Fast-Track Access to the UK Market

Clinical Trials - Regulatory

MHRA's International Recognition Procedure: Fast-Track Access to the UK Market

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1764696930757, hs_published_at=1767769678459, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/John%20McIntyre.png',altText='John McIntyre',fileId=201584594055}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=65160865}, second={hs_id=200435431440, hs_child_table_id=0, hs_updated_at=1763745269993, hs_published_at=1767769678459, avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/AQ_GlobalAccess_AlexGrosvenor-3.jpg',altText='AQ_GlobalAccess_AlexGrosvenor-3',fileId=182031301743}, lastname=Grosvenor, hs_initial_published_at=1763745278294, hs_created_by_user_id=26433386, hs_created_at=1763745229272, hs_is_edited=false, hs_deleted_at=0, name=Alex, job=Alex Grosvenor is a Senior Vice President and Managing Director at Precision AQ. Based in London, Alex leads the International Pricing & Market Access Strategy team, which he established in September 2015. Over the past decade, he has built this team into a successful, thriving practice, with a reputation for delivering high-quality work and excellent recommendation for its clients. Alex brings more than 20 years’ consulting experience in the biopharmaceutical industry, over 15 of these in pricing & market access.He specialises in complex pricing strategies, including cross-indication strategy, launch-sequencing and international price referencing. He has worked across multiple therapy areas, including oncology, immunology, cardiovascular, orphan indications and cell & gene therapies., slug=alex-grosvenor, hs_updated_by_user_id=65160865}, third={}})
  • John M. avatar

    John M.

  • Alex G. avatar

    Alex G.

Discover
Read: New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained

Clinical Trials

New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=167906611101, hs_child_table_id=0, hs_updated_at=1762899997332, hs_published_at=1767769678459, description=Helen brings over 30 years of experience in multinational healthcare, biotech, and pharmaceutical industries, including work with Medical Research Institutes and CROs. She specializes in leading clinical research, drug and device development, and fostering innovative research collaborations. Based in Sydney, Australia, Helen has a strong track record of delivering clinical trials across the APAC region., avatar=Image{width=600,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Helene-Ormandy.png',altText='Helene-Ormandy',fileId=168387434767}, lastname=Ormandy, PhD, hs_initial_published_at=1716212950394, hs_created_by_user_id=2737751, hs_created_at=1716212897654, hs_is_edited=false, hs_deleted_at=0, name=Helen, job=Executive Director, Clinical Operations, slug=helen-ormandy, hs_updated_by_user_id=65160865}, second={hs_id=197935898186, hs_child_table_id=0, hs_updated_at=1761062728726, hs_published_at=1767769678459, description=Hardik Badani is a seasoned clinical research professional with a proven track record in managing complex, multi-regional clinical trials across North America, Europe, Asia-Pacific, and Africa. Based in Singapore, Hardik brings over a decade of experience in clinical operations, portfolio oversight, and project finance. He is a certified Project Management Professional (PMP) and was recognized with the Bronze award at the 2020 PharmaTimes International Clinical Researcher of the Year competition. Hardik’s expertise spans the full spectrum of clinical trial delivery—from startup through closeout—with a strong command of clinical systems including CTMS and EDC platforms. His leadership style emphasizes collaboration, operational excellence, and a deep commitment to advancing global health through precision-driven research., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hardik%20Badani.png',altText='Hardik Badani',fileId=197937156662}, lastname=Badani, hs_initial_published_at=1761062733198, hs_created_by_user_id=26433386, hs_created_at=1761062663685, hs_is_edited=false, hs_deleted_at=0, name=Hardik, job=Principal Clinical Trial Manager, slug=hardik-badani, hs_updated_by_user_id=65160865}, third={}})
  • Helen O. avatar

    Helen O.

  • Hardik B. avatar

    Hardik B.

Discover

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore